Topoizomeraz İnhibitörlerinin Klinik Kullanımları ve Yan Etki Yönetimleri
Özet
Topoizomeraz I ve II enzimleri, DNA yapısındaki geçici kesiler ve birleşmeler aracılığıyla genetik materyalin topolojik dönüşümlerini kontrol eden hayati biyokimyasal yapılardır. Bu katalitik mekanizmada topoizomeraz I tek bir DNA zincirini kırarken, topoizomeraz II çift zincir kırığı oluşturur ve işlevini yerine getirmek için ek moleküler enerji kaynağı olan ATP'ye ihtiyaç duyar. Son yıllarda geliştirilen antineoplastik tedavi protokollerinde, bu enzimlerin katalitik döngülerini hedef alan inhibitör ajanlar onkoloji ve hematoloji kliniklerinde geniş yer edinmiştir. FDA tarafından klinik onay almış topoizomeraz II inhibitörleri arasında etoposid, teniposid, antrasiklinler (doksorubisin, daunorubisin, epirubisin, idarubisin) ve mitoksantron bulunurken; irinotekan ve topotekan ise topoizomeraz I'i hedef alan temel ajanlar arasındadır. Bu kemoterapötik ajanlar akciğer, meme, over ve kolorektal gibi solid tümörlerin yanı sıra lösemi ve lenfoma gibi malignitelerde başarıyla uygulanmaktadır. Ancak, güçlü antitümöral etkilerinin yanında miyelosupresyon, ciddi gastrointestinal semptomlar ve antrasiklinlere bağlı gelişebilen geri dönüşsüz kardiyotoksisite gibi doz sınırlayıcı toksisitelere yol açabilirler. Bu nedenle klinik pratik süreçlerinde hastaların organ fonksiyonlarının yakından takibi, kreatinin klirensi ile ejeksiyon fraksiyonu ölçümleri ve her hastaya özgü bireyselleştirilmiş doz ayarlamaları kritik önem taşır.
Topoisomerase I and II enzymes are vital biochemical structures that control the topological transformations of genetic material through temporary breaks and religations in the DNA structure. In this catalytic mechanism, while topoisomerase I cleaves a single DNA strand, topoisomerase II creates a double-strand break and requires ATP as an additional molecular energy source to function. In recent antineoplastic treatment protocols, inhibitor agents targeting the catalytic cycles of these enzymes have gained a widespread place in oncology and hematology clinics. FDA-approved topoisomerase II inhibitors include etoposide, teniposide, anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin), and mitoxantrone, whereas irinotecan and topotecan are primary agents targeting topoisomerase I. These chemotherapeutic agents are successfully applied in malignancies such as leukemia and lymphoma, as well as solid tumors including lung, breast, ovarian, and colorectal cancers. However, along with their potent antitumor efficacy, they can cause dose-limiting toxicities such as myelosuppression, severe gastrointestinal symptoms, and irreversible anthracycline-induced cardiotoxicity. Therefore, close monitoring of organ functions, evaluation of creatinine clearance and ejection fraction, and individualized dose adjustments tailored to each patient are of critical importance in clinical practice.
Referanslar
Pommier, Y. (2012). DNA topoisomerases and cancer, Springer, Berlin.
Cuya, S. M., Bjornsti, M. A., van Waardenburg, R. C. (2017). DNA topoisomerase-targeting chemotherapeutics: what’s new? Cancer chemotherapy and pharmacology, 80 (1), 1-14.
Baker, N. M., Rajan, R., Mondragon, A. (2009). Structural studies of type I topoisomerases. Nucleic acids research, 37(3), 693-701.
Hande, K. R. (2008). Topoisomerase II inhibitors. Update on cancer therapeutics, 3(1), 13- 26.
Shu B, Yu Q, Hu DX, Che T, Zhang SS, Li D. Synthesis and biological evaluation of novel indole-pyrazoline hybrid derivatives as potential topoisomerase 1 inhibitors. Bioorg Med Chem Lett. 2020;30(4):126925
Hande KR. Etoposide: four decades of development of a topoisomerase II inhibitor. Eur J Cancer 1998; 34:1514–21.
Frost BM, Forestier E, Gustafsson G, Nygen P, Hellebostad M, Jomsson OG, et al. Translation t (12:21) is related to in vitro cellular drug sensitivity to doxorubicin and etoposide in childhood acute lymphocytic leukemia. Blood 2004; 104: 2452–7.
Pfeundschuh M, Trumper L, Kloess M, Schmits R, Schmits R, Fellrr AC, et al. Two-weekly or 3-weekly CHOP with or without etoposide for the treatment of young patients with good prognosis aggressive lymphomas: results of NHL-B1 trial of the DSHINIL. Blood 2004; 104:626–33.
Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Tarley H, et al. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase II alpha expression. Clin Cancer Res 2003; 9:4682–8.
Muggia FM. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother Pharmacol 1994;34(Suppl: S127–33.
Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, Lewinski T, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy—a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18: 3400–8.
Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984;226: 466–8
Crivellari D, Lombardi D, Spazzapam S, Veronesi A, Toffoli G. New oral drugs in older patients: a review of idarubicin in elderly patients. Crit Rev Oncol Hematol 2004;49: 153–63
Danesi R, Fogli S, Gennari A, Conte P, del Tacca M. Pharmacokinetic–pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002; 41:431–44
Wiseman LR, Spencer CM. Dexrazoxane. A review of its use as a cardio protective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998; 56:385–403.
Delgado, J. L., Hsieh, C. M., Chan, N. L., Hiasa, H. (2018). Topoisomerases as anticancer targets. Biochemical Journal, 475(2), 373-398.
L.M. Wagner, Fifteen years of irinotecan therapy for pediatric sarcoma: where to next? Clin. Sarcoma Res. 5 (2015) 20
L. Miele, A. Liguori, G. Marrone, M. Biolato, C. Araneo, F.G. Vaccaro, et al., Fatty liver and drugs: the two sides of the same coin, Eur. Rev. Med. Pharmacol. Sci. 21 (2017) 86–94.
D.B. Zhen, R.L. McDevitt, M.M. Zalupski, V. Sahai, Irinotecan-associated dysarthria: a single institution case series with management implications in patients with gastrointestinal malignancies, J. Oncol. Pharm. Pract. 25 (2019) 980–986.
D.B. Zhen, R.L. McDevitt, M.M. Zalupski, V. Sahai, Irinotecan-associated dysarthria: a single institution case series with management implications in patients with gastrointestinal malignancies, J. Oncol. Pharm. Pract. 25 (2019) 980–986.
C. Cheng, J.E. Lau, M.A. Earl, Use of atropine-diphenoxylate compared with hyoscyamine to decrease rates of irinotecan-related cholinergic syndrome, J. Community Support. Oncol. 13 (2015) 3–7.
M. Harel, J.L. Hyatt, B. Brumshtein, C.L. Morton, K.J. Yoon, R.M. Wadkins, et al., The crystal structure of the complex of the anticancer prodrug 7-ethyl-10- [4-(1- piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action, Mol. Pharmacol. 67 (2005) 1874–1881.
Y. Kanbayashi, T. Ishikawa, M. Kanazawa, Y. Nakajima, Y. Tabuchi, R. Kawano, et al., Predictive factors for the development of irinotecan-related cholinergic syndrome using ordered logistic regression analysis, Med. Oncol. 35 (2018) 82.
J. Andreyev, P. Ross, C. Donnellan, E. Lennan, P. Leonard, C. Waters, et al., Guidance on the management of diarrhoea during cancer chemotherapy, Lancet Oncol. 15 (2014) 447–460.
Eng WK, Faucette L, Johnson RK, Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol 1988; 34: 755–60.
